People: Omeros Corp (OMER.W)

OMER.W on CBOE When Trading NASDAQ Global Select Market

5.56USD
22 May 2013
Price Change (% chg)

$0.20 (+3.73%)
Prev Close
$5.36
Open
$5.56
Day's High
$5.56
Day's Low
$5.56
Volume
100
Avg. Vol
922
52-wk High
$13.37
52-wk Low
$3.67

Search Stocks

Summary

Name Age Since Current Position

Gregory Demopulos

 54 2010 Chairman of the Board, President, Chief Executive Officer, Interim CFO, Treasurer

Marcia Kelbon

 53 2007 Vice President - Patent, General Counsel, Secretary

Thomas Cable

 72 Lead Independent Director

Peter Demopulos

 58 1995 Director

Arnold Hanish

 2012 Director

Ray Aspiri

 75 2007 Independent Director

Leroy Hood

 73 2001 Independent Director
» Insider Trading

Biographies

Name Description

Gregory Demopulos

 Dr. Gregory A. Demopulos, M.D., is Chairman of the Board, President, Chief Executive Officer, Interim Chief Financial Officer and Treasurer of Omeros Corporation. He also served as chief medical officer from June 1994 to March 2010. Prior to founding Omeros, Dr. Demopulos completed his residency in orthopedic surgery at Stanford University and his fellowship training at Duke University. Dr. Demopulos currently serves on the board of directors of Onconome, Inc., a privately held company developing biomarkers for early cancer detection. Dr. Demopulos received his M.D. from the Stanford University School of Medicine and his B.S. from Stanford University.

Marcia Kelbon

 Ms. Marcia S. Kelbon, J.D., is Vice President - Patent, General Counsel, Secretary of Omeros Corp. Prior to that, Ms. Kelbon was a partner with the firm of Christensen O’Connor Johnson & Kindness, PLLC, where she specialized in U.S. and international intellectual property procurement, management, licensing and enforcement issues. Ms. Kelbon received her J.D. and her M.S. in chemical engineering from the University of Washington and her B.S. from The Pennsylvania State University.

Thomas Cable

 Mr. Thomas J. Cable is Lead Independent Director of Omeros Corporation. He has served on board of directors since January 1995. He has also served on audit committee since January 1995 and on compensation committee since December 2007. In addition, Mr. Cable has served as chairman of nominating and governance committee since September 2009. Mr. Cable is the chairman of the board of the Washington Research Foundation, a technology transfer and early stage venture capital organization affiliated with the University of Washington, which he co-founded in 1980. Mr. Cable also founded Cable & Howse Ventures, a venture capital firm, and Cable, Howse & Ragen, an investment banking firm. In addition, Mr. Cable co-founded Montgomery Securities, an investment banking firm acquired by Bank of America. A former U.S. Navy submarine officer, Mr. Cable received his M.B.A. from the Stanford Graduate School of Business and his B.A. from Harvard University.

Peter Demopulos

 Dr. Peter A. Demopulos, M.D., FACC, FSCAI, is Director of Omeros Corporation since January 1995. Dr. Demopulos is a practicing board-certified general and interventional cardiologist at Seattle Cardiology, part of the Swedish Heart & Vascular Institute. He has been a member of Seattle Cardiology from 2005 to the present, also serving as its Medical Director from 2005 to 2010. From 1989 to 2005, Dr. Demopulos practiced cardiology at Minor & James Medical PLLC. Dr. Demopulos is also a clinical assistant professor of cardiology at the University of Washington School of Medicine, a position that he has held since 1989. He participates as an investigator in clinical trials evaluating interventional cardiology devices and drug therapies at Seattle Cardiovascular Research and Swedish Cardiovascular Research. Dr. Demopulos received his M.D. from the Stanford University School of Medicine and his B.S. from Stanford University.

Arnold Hanish

 Mr. Arnold C. Hanish has been appointed as Director of Omeros Corp., effective 26 September 2012. Mr. Hanish has over 40 years of experience in finance. He currently serves as vice president, chief accounting officer, at Eli Lilly and Company, a position he has held since 1994. Prior to his appointment as chief accounting officer, he held a number of senior financial positions at Eli Lilly. Before Eli Lilly, Mr. Hanish was with Arthur Young & Company (currently Ernst & Young) for nearly 14 years. Mr. Hanish is a member of the Standing Advisory Group of the Public Company Accounting Oversight Board (PCAOB). In addition, he is the immediate past chairperson of Financial Executives International's (FEI's) Committee on Corporate Reporting, a position he held from 2007 to 2010. Mr. Hanish earned his B.A. in accounting from the University of Cincinnati.

Ray Aspiri

 Mr. Ray Aspiri is Independent Director of Omeros Corporation since January 1995. He was treasurer from January 1999 to September 2007. Mr. Aspiri has also served as chairman of compensation committee since January 1995, as a member of nominating and governance committee since September 2009 and as a member of audit committee since July 2011. Mr. Aspiri is the chairman of the board of Tempress Technologies, Inc., a privately held research and development company specializing in high-pressure fluid dynamics for the oil and gas industry, which he founded in 1997. From 1980 to 1997, Mr. Aspiri served as the chairman of the board and chief executive officer of Tempress, Inc., a privately held company specializing in products for the truck, marine and sporting goods industries.

Leroy Hood

 Dr. Leroy E. Hood, M.D., Ph.D., is Independent Director of Omeros Corporation since March 2001. He also has served on nominating and governance committee since September 2009 and on compensation committee since July 2011. Dr. Hood previously served as a member of audit committee from September 2009 to December 2009. Dr. Hood is the president of the Institute for Systems Biology, a non-profit research institute dedicated to the study and application of systems biology, which he co-founded in 2000. Previously, Dr. Hood was founder and chairman of the Department of Molecular Biotechnology at the University of Washington School of Medicine. Dr. Hood also co-founded Amgen, Inc., Applied Biosystems, Inc., Darwin Molecular Technologies, Inc., Rosetta Inpharmatics, Inc. and SyStemix, Inc. Dr. Hood is a member of the National Academy of Sciences, the American Philosophical Society, the American Association of Arts and Sciences, the Institute of Medicine and the National Academy of Engineering. Dr. Hood received his Ph.D. and B.S. from the California Institute of Technology and his M.D. from The John Hopkins School of Medicine.

Basic Compensation

Name Fiscal Year Total

Gregory Demopulos

 617,349

Marcia Kelbon

 313,813

Thomas Cable

 --

Peter Demopulos

 --

Arnold Hanish

 --

Ray Aspiri

 --

Leroy Hood

 --
As Of 30 Dec 2011

Options Compensation

Name Options Value

Gregory Demopulos

 0 0

Marcia Kelbon

 0 0

Thomas Cable

 0 0

Peter Demopulos

 0 0

Arnold Hanish

 0 0

Ray Aspiri

 0 0

Leroy Hood

 0 0

Insider Trading

Name Shares Traded Price

KELBON MARCIA S

 5,103 $0.98

CABLE THOMAS J

 5,000 $3.98

CABLE THOMAS J

 5,000 $6.19

ASPIRI RAY

 40,000 $5.72

KELBON MARCIA S

 10,000 $0.98

HANISH ARNOLD C

 2,000 $5.58

DEMOPULOS PETER A

 9,345 $5.42

DEMOPULOS GREGORY A

 10,000 $0.98

CABLE THOMAS J

 5,000 $9.60

CABLE THOMAS J

 2,000 $0.00

DEMOPULOS GREGORY A

 14,635 $10.25

DEMOPULOS GREGORY A

 6,666 $7.56

DEMOPULOS GREGORY A

 5,000 $5.92

DEMOPULOS GREGORY A

 10,000 $0.98

DEMOPULOS GREGORY A

 1,542 $0.52
» Full list on Insider Trading
Search Stocks